{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:37:05Z","timestamp":1776742625644,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["97-01-05-18056"],"award-info":[{"award-number":["97-01-05-18056"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["98-01-05-19879"],"award-info":[{"award-number":["98-01-05-19879"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00520-022-06832-x","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T08:25:49Z","timestamp":1642407949000},"page":"3865-3873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FLOT (a chemotherapy regimen for gastric\/esophagogastric junction cancer): to be treated as a highly emetogenic regimen or a moderately emetogenic one? Comparison of the emetogenic potential of FLOT versus FOLFOX and TAC regimens"],"prefix":"10.1007","volume":"30","author":[{"given":"Marziyeh","family":"Ghorbani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noushin","family":"Fahimfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soha","family":"Namazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Dehshahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"6832_CR1","doi-asserted-by":"publisher","unstructured":"Rhodes VA, McDaniel RW (2001) Nausea, vomiting, and retching: complex problems in palliative care. CA-Caner J Clin 51(4):232\u201348; quiz 49\u201352. https:\/\/doi.org\/10.3322\/canjclin.51.4.232","DOI":"10.3322\/canjclin.51.4.232"},{"issue":"3","key":"6832_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/s1470-2045(15)00520-3","volume":"17","author":"G Kov\u00e1cs","year":"2016","unstructured":"Kov\u00e1cs G, Wachtel AE, Basharova EV et al (2016) Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol 17(3):332\u2013344. https:\/\/doi.org\/10.1016\/s1470-2045(15)00520-3","journal-title":"Lancet Oncol"},{"key":"6832_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","volume":"722","author":"D Warr","year":"2014","unstructured":"Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192\u2013196. https:\/\/doi.org\/10.1016\/j.ejphar.2013.10.015","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"6832_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.6004\/jnccn.2009.0039","volume":"10","author":"DS Ettinger","year":"2012","unstructured":"Ettinger DS, Armstrong DK, Barbour S et al (2012) Antiemesis. JNCCN J Natl Compr Cancer Netw 10(4):456\u2013485. https:\/\/doi.org\/10.6004\/jnccn.2009.0039","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"3","key":"6832_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00417474","volume":"2","author":"J Pater","year":"1994","unstructured":"Pater J, Slamet L, Zee B et al (1994) Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 2(3):161\u2013166. https:\/\/doi.org\/10.1007\/BF00417474","journal-title":"Support Care Cancer"},{"issue":"1","key":"6832_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/jco.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109. https:\/\/doi.org\/10.1200\/jco.1997.15.1.103","journal-title":"J Clin Oncol"},{"issue":"1","key":"6832_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj078","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20\u201328. https:\/\/doi.org\/10.1093\/annonc\/mdj078","journal-title":"Ann Oncol"},{"issue":"28","key":"6832_CR8","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"issue":"14","key":"6832_CR9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"issue":"10184","key":"6832_CR10","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 393(10184):1948\u20131957. https:\/\/doi.org\/10.1016\/s0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"6832_CR11","unstructured":"World Health Organization: International Agency for Research on Cancer. Stomach Cancer. The Global Cancer Observatory. https:\/\/gco.iarc.fr\/today\/fact-sheets-cancers. [updated December, 2020; cited July 12, 2021]"},{"key":"6832_CR12","doi-asserted-by":"publisher","unstructured":"Uson Junior PLS, Santos VM, Bugano DDG et al (2019) Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors. Sci Rep 9(1):15806-. https:\/\/doi.org\/10.1038\/s41598-019-52334-y","DOI":"10.1038\/s41598-019-52334-y"},{"issue":"10","key":"6832_CR13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51(10):1274\u20131282. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.024","journal-title":"Eur J Cancer"},{"issue":"4","key":"6832_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00520-017-3950-y","volume":"26","author":"JS Bubalo","year":"2018","unstructured":"Bubalo JS, Herrington JD, Takemoto M et al (2018) Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. Support Care Cancer 26(4):1273\u20131279. https:\/\/doi.org\/10.1007\/s00520-017-3950-y","journal-title":"Support Care Cancer"},{"issue":"2","key":"6832_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdx698","volume":"29","author":"L Zhang","year":"2018","unstructured":"Zhang L, Lu S, Feng J et al (2018) A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 29(2):452\u2013458. https:\/\/doi.org\/10.1093\/annonc\/mdx698","journal-title":"Ann Oncol"},{"issue":"6","key":"6832_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/ecc.12147","volume":"23","author":"S Moradian","year":"2014","unstructured":"Moradian S, Shahidsales S, GhavamNasiri MR et al (2014) Translation and psychometric assessment of the Persian version of the Rhodes index of nausea, vomiting and retching (INVR) scale for the assessment of chemotherapy-induced nausea and vomiting. Eur J Cancer Care (Engl) 23(6):811\u2013818. https:\/\/doi.org\/10.1111\/ecc.12147","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"11","key":"6832_CR17","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","volume":"19","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Hofheinz R et al (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19(11):1882\u20131887. https:\/\/doi.org\/10.1093\/annonc\/mdn403","journal-title":"Ann Oncol"},{"issue":"11","key":"6832_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00535-012-0746-1","volume":"48","author":"K Oyama","year":"2013","unstructured":"Oyama K, Fushida S, Kaji M et al (2013) Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. J Gastroenterol 48(11):1234\u20131241. https:\/\/doi.org\/10.1007\/s00535-012-0746-1","journal-title":"J Gastroenterol"},{"issue":"3","key":"6832_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s005200050157","volume":"6","author":"PJ Hesketh","year":"1998","unstructured":"Hesketh PJ, Gralla RJ, du Bois A et al (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6(3):221\u2013227. https:\/\/doi.org\/10.1007\/s005200050157","journal-title":"Support Care Cancer"},{"key":"6832_CR20","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2147\/dddt.s243924","volume":"14","author":"MJ Yang","year":"2020","unstructured":"Yang MJ, Xu HR, Li H et al (2020) Comparison of pharmacokinetics of aprepitant in healthy Chinese and Caucasian subjects. Drug Des Devel Ther 14:1219\u20131226. https:\/\/doi.org\/10.2147\/dddt.s243924","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"6832_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5\u20139. https:\/\/doi.org\/10.1007\/s00520-018-4131-3","journal-title":"Support Care Cancer"},{"issue":"12","key":"6832_CR22","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/jco.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822\u20132830. https:\/\/doi.org\/10.1200\/jco.2005.09.050","journal-title":"J Clin Oncol"},{"issue":"9","key":"6832_CR23","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","volume":"23","author":"Y Escobar","year":"2015","unstructured":"Escobar Y, Cajaraville G, Virizuela JA et al (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (actual data of vomiting incidence by chemotherapy evaluation) study. Support Care Cancer 23(9):2833\u20132840. https:\/\/doi.org\/10.1007\/s00520-015-2809-3","journal-title":"Support Care Cancer"},{"issue":"2","key":"6832_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dote.12482","volume":"30","author":"Y Baba","year":"2017","unstructured":"Baba Y, Baba H, Yamamoto S et al (2017) Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Dis Esophagus 30(2):1\u20137. https:\/\/doi.org\/10.1111\/dote.12482","journal-title":"Dis Esophagus"},{"issue":"24","key":"6832_CR25","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38(24):2782\u20132797. https:\/\/doi.org\/10.1200\/jco.20.01296","journal-title":"J Clin Oncol"},{"key":"6832_CR26","unstructured":"Aaparo M GR HJ, Molassiotis A, Roila F. MASCC\/ESMO antiemetic guidelines. MASCC: Multinational Association for Supportive Care in Cancer. https:\/\/www.mascc.org\/antiemetic-guidelines. [updated July, 2019; cited May, 2021]"},{"key":"6832_CR27","unstructured":"NCCN Antiemesis Panel Members. NCCN Guidelines Version 2.2020, Antiemesis. NCCN: National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. [updated April 23, 2020; cited December, 2020]"},{"key":"6832_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","volume":"722","author":"K Jordan","year":"2014","unstructured":"Jordan K, Gralla R, Jahn F et al (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197\u2013202. https:\/\/doi.org\/10.1016\/j.ejphar.2013.09.073","journal-title":"Eur J Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06832-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06832-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T07:13:32Z","timestamp":1648019612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06832-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6832"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06832-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and then approved by the Institutional Review Board of each study center and \u201cIran National Committee for Ethics in Biomedical Research\u201d (approval ID: IR.SUMS.REC.1397.662 and IR.SUMS.REC.1398.623). This study is conducted in compliance with the principles of the Declaration of Helsinki and the national norms and standards for conducting medical research in Iran.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}